vs
Arcellx, Inc.（ACLX）与Alector, Inc.（ALEC）财务数据对比。点击上方公司名可切换其他公司
Alector, Inc.的季度营收约是Arcellx, Inc.的3.8倍（$6.2M vs $1.7M）。Alector, Inc.净利率更高（-597.5% vs -3513.4%，领先2915.9%）。Alector, Inc.同比增速更快（-88.5% vs -89.2%）。过去两年Alector, Inc.的营收复合增速更高（-37.4% vs -79.5%）
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
Alector是一家临床阶段生物制药企业，专注于神经退行性疾病的免疫疗法研发，管线覆盖阿尔茨海默病、额颞叶痴呆、帕金森病等未被满足的医疗需求，主要在美国运营，与全球药企合作推进候选药物的临床试验。
ACLX vs ALEC — 直观对比
营收规模更大
ALEC
是对方的3.8倍
$1.7M
营收增速更快
ALEC
高出0.7%
-89.2%
净利率更高
ALEC
高出2915.9%
-3513.4%
两年增速更快
ALEC
近两年复合增速
-79.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7M | $6.2M |
| 净利润 | $-58.1M | $-37.3M |
| 毛利率 | — | — |
| 营业利润率 | -3850.2% | -634.4% |
| 净利率 | -3513.4% | -597.5% |
| 营收同比 | -89.2% | -88.5% |
| 净利润同比 | -23.4% | -1696.9% |
| 每股收益（稀释后） | $-1.01 | $-0.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLXALEC
| Q4 25 | $1.7M | $6.2M | ||
| Q3 25 | $4.9M | $3.3M | ||
| Q2 25 | $7.6M | $7.9M | ||
| Q1 25 | $8.1M | $3.7M | ||
| Q4 24 | $15.3M | $54.2M | ||
| Q3 24 | $26.0M | $15.3M | ||
| Q2 24 | $27.4M | $15.1M | ||
| Q1 24 | $39.3M | $15.9M |
净利润ACLXALEC
| Q4 25 | $-58.1M | $-37.3M | ||
| Q3 25 | $-55.8M | $-34.7M | ||
| Q2 25 | $-52.8M | $-30.5M | ||
| Q1 25 | $-62.3M | $-40.5M | ||
| Q4 24 | $-47.1M | $-2.1M | ||
| Q3 24 | $-25.9M | $-42.2M | ||
| Q2 24 | $-27.2M | $-38.7M | ||
| Q1 24 | $-7.2M | $-36.1M |
营业利润率ACLXALEC
| Q4 25 | -3850.2% | -634.4% | ||
| Q3 25 | -1248.3% | -1153.6% | ||
| Q2 25 | -777.4% | -433.6% | ||
| Q1 25 | -847.6% | -1216.5% | ||
| Q4 24 | -348.2% | -13.4% | ||
| Q3 24 | -129.1% | -315.7% | ||
| Q2 24 | -127.8% | -302.4% | ||
| Q1 24 | -40.3% | -275.0% |
净利率ACLXALEC
| Q4 25 | -3513.4% | -597.5% | ||
| Q3 25 | -1127.1% | -1063.4% | ||
| Q2 25 | -698.6% | -387.7% | ||
| Q1 25 | -766.0% | -1101.6% | ||
| Q4 24 | -308.4% | -3.8% | ||
| Q3 24 | -99.4% | -275.2% | ||
| Q2 24 | -99.3% | -256.4% | ||
| Q1 24 | -18.3% | -227.0% |
每股收益（稀释后）ACLXALEC
| Q4 25 | $-1.01 | $-0.34 | ||
| Q3 25 | $-0.99 | $-0.34 | ||
| Q2 25 | $-0.94 | $-0.30 | ||
| Q1 25 | $-1.13 | $-0.41 | ||
| Q4 24 | $-0.87 | $-0.02 | ||
| Q3 24 | $-0.48 | $-0.43 | ||
| Q2 24 | $-0.51 | $-0.40 | ||
| Q1 24 | $-0.14 | $-0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.3M | $256.0M |
| 总债务越低越好 | — | $10.0M |
| 股东权益账面价值 | $402.4M | $30.6M |
| 总资产 | $604.0M | $293.2M |
| 负债/权益比越低杠杆越低 | — | 0.33× |
8季度趋势，按日历期对齐
现金及短期投资ACLXALEC
| Q4 25 | $450.3M | $256.0M | ||
| Q3 25 | $461.4M | $291.1M | ||
| Q2 25 | $453.1M | $307.3M | ||
| Q1 25 | $543.3M | $354.6M | ||
| Q4 24 | $587.4M | $413.4M | ||
| Q3 24 | $574.3M | $457.2M | ||
| Q2 24 | $516.7M | $503.3M | ||
| Q1 24 | $573.9M | $562.1M |
总债务ACLXALEC
| Q4 25 | — | $10.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $10.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ACLXALEC
| Q4 25 | $402.4M | $30.6M | ||
| Q3 25 | $440.8M | $57.7M | ||
| Q2 25 | $392.2M | $71.2M | ||
| Q1 25 | $416.9M | $94.6M | ||
| Q4 24 | $454.8M | $126.8M | ||
| Q3 24 | $483.0M | $118.9M | ||
| Q2 24 | $487.2M | $150.6M | ||
| Q1 24 | $496.6M | $178.9M |
总资产ACLXALEC
| Q4 25 | $604.0M | $293.2M | ||
| Q3 25 | $655.9M | $335.3M | ||
| Q2 25 | $619.1M | $356.4M | ||
| Q1 25 | $648.1M | $408.3M | ||
| Q4 24 | $711.3M | $468.3M | ||
| Q3 24 | $764.9M | $516.0M | ||
| Q2 24 | $734.3M | $570.7M | ||
| Q1 24 | $779.7M | $635.5M |
负债/权益比ACLXALEC
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-58.2M | $-41.7M |
| 自由现金流经营现金流 - 资本支出 | $-58.9M | — |
| 自由现金流率自由现金流/营收 | -3563.4% | — |
| 资本支出强度资本支出/营收 | 46.2% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-212.6M | — |
8季度趋势，按日历期对齐
经营现金流ACLXALEC
| Q4 25 | $-58.2M | $-41.7M | ||
| Q3 25 | $-49.2M | $-32.5M | ||
| Q2 25 | $-39.7M | $-49.0M | ||
| Q1 25 | $-63.1M | $-60.8M | ||
| Q4 24 | $-46.0M | $-55.0M | ||
| Q3 24 | $30.7M | $-50.7M | ||
| Q2 24 | $-36.2M | $-62.8M | ||
| Q1 24 | $-31.9M | $-61.3M |
自由现金流ACLXALEC
| Q4 25 | $-58.9M | — | ||
| Q3 25 | $-49.5M | $-32.5M | ||
| Q2 25 | $-40.2M | $-49.1M | ||
| Q1 25 | $-63.9M | $-60.8M | ||
| Q4 24 | $-47.5M | $-55.2M | ||
| Q3 24 | $28.4M | $-50.9M | ||
| Q2 24 | $-39.5M | $-63.1M | ||
| Q1 24 | $-38.3M | $-61.9M |
自由现金流率ACLXALEC
| Q4 25 | -3563.4% | — | ||
| Q3 25 | -1000.3% | -997.6% | ||
| Q2 25 | -532.4% | -623.0% | ||
| Q1 25 | -786.4% | -1655.0% | ||
| Q4 24 | -311.3% | -101.8% | ||
| Q3 24 | 109.2% | -332.1% | ||
| Q2 24 | -144.1% | -418.6% | ||
| Q1 24 | -97.7% | -389.3% |
资本支出强度ACLXALEC
| Q4 25 | 46.2% | 0.0% | ||
| Q3 25 | 6.0% | 0.3% | ||
| Q2 25 | 6.4% | 0.1% | ||
| Q1 25 | 9.6% | 0.5% | ||
| Q4 24 | 9.8% | 0.3% | ||
| Q3 24 | 8.8% | 1.4% | ||
| Q2 24 | 11.7% | 2.2% | ||
| Q1 24 | 16.4% | 3.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
